Exosome material is applied by your practitioner during the appointment, and practices give their own instructions about retinol and other strong actives for the days around a procedure such as microneedling [1, 2]. So the usual answer to exosomes before or after retinol is that the exosome step happens in the clinic, and your provider tells you when to pause your retinol and when it can restart.
The exact timing varies from practice to practice [2], and as of 9 November 2026 no located study has tested the timing of exosome material applied at a procedure against a home retinol, tretinoin or vitamin C routine. This guide explains why practices plan around these products, how cosmetic retinol differs from prescription tretinoin, what the published reports say about vitamin C and microneedling, and which questions to bring to your provider and your prescriber.
Regulatory position
The FDA stated in its 2019 public safety notification that there are currently no FDA-approved exosome products [19]. ExaVeyra Sciences supplies exosome material to licensed practitioners, described by its available formats. Decisions about your skincare routine, and any change to a prescription, belong with your provider and your prescriber, and this guide makes no such decision.
Understanding why practices pause strong actives around a procedure
Microneedling opens many tiny channels in the outer layer of the skin, and for a time that layer holds back less of whatever is placed on it. Gupta and colleagues measured this with small microneedle arrays in human volunteers in 2011 and reported that uncovered sites regained their barrier within about two hours, while covered sites stayed open for 3 to 40 hours depending on the needles used [15]. The Nikolis expert panel noted in 2026 that the micropores from microneedling may need several days before the barrier is completely restored [1].
Retinoids change that same outer layer. Kong and colleagues reported in a 2016 biopsy study that both retinol and retinoic acid thickened the epidermis over four weeks [10], and the prescribing information for topical tretinoin states that it can cause dryness, redness, swelling, peeling, itching, burning or stinging on its own [9]. A fresh procedure on skin that is already reacting to an active combines two sources of irritation, which is the reasoning practices give for a pause.
Published procedure guides build skincare into the plan for that reason. Alster and Graham’s 2018 practical guide to microneedling sets out pretreatment recommendations and postoperative considerations as part of the procedure itself, so the days before and after a session belong to the plan [3].
The most recent published guidance comes from Nikolis and colleagues, who reviewed 104 publications and convened a panel of dermatologists and plastic surgeons, publishing in 2026. They reported that cleansers, moisturizers, antioxidant serums and sunscreens were among the common products around procedures, that high-evidence data were limited, and that very few studies compared a routine with no skincare at all; five of the authors work for a skincare company, as the references note [1].
Practices also differ from one another. Gold and colleagues surveyed dermatologists and plastic surgeons in 2019 and reported in 2020 that skin preparation and aftercare for microneedling, peels and similar procedures were inconsistent, with no standard of care observed [2]. Even within one panel the advice depends on the procedure and the skin: the Nikolis panel described preprocedural tretinoin as a possible aid to chemical peels in lighter skin while advising that retinoids be stopped 1 to 2 weeks before peeling in darker skin [1]. That variation is why two practices can give you two different answers, and why the instructions from your own provider are the ones to follow.
Understanding the difference between retinol and tretinoin
Retinol and tretinoin are close chemical relatives with different legal standing. Retinol is widely used in skincare products [10], while topical tretinoin is an FDA-approved prescription drug [9], and the FDA explains that whether a product is a cosmetic or a drug under the law is determined by its intended use [12].
Retinol is a precursor of retinoic acid, the active molecule in tretinoin, as Kong and colleagues described in 2016. They reported that both raised collagen gene and protein expression in the skin over four weeks, with changes from retinol that tended to be smaller than those from retinoic acid; most of the study’s authors worked in a consumer products company’s research division [10].
Strength tends to travel with irritation. Mukherjee and colleagues reviewed the retinoid family in 2006 and described irritant reactions such as burning, scaling or dermatitis as a limit on how readily patients accept these ingredients, a problem more prominent with tretinoin and tazarotene than with retinol or retinaldehyde [11].
For a patient, the practical difference is who decides. A retinol serum is a skincare product your procedure provider can ask you to pause, while tretinoin was prescribed for you by a clinician, and any change to it belongs with that clinician.
Prescription retinoids remain a conversation with the prescriber
Published guidance on retinoids and procedures has changed as evidence accumulated, and the clearest example concerns oral isotretinoin. Waldman and colleagues reported for an American Society for Dermatologic Surgery task force in 2017 that the package insert advised stopping the drug for six months before cosmetic procedures, and the task force concluded that the evidence was insufficient to justify delaying superficial chemical peels and nonablative lasers [8].
Spring and colleagues reviewed 32 publications covering 1,485 procedures the same year and reached a similar conclusion for several procedures, while still advising against mechanical dermabrasion and fully ablative laser during treatment with the drug [7]. Those reviews concern an oral medicine, and they show why timing around a prescription retinoid is a judgment the prescriber and the procedure provider make together with the patient.
For topical tretinoin, the label states that the drug can cause local skin irritation, including dryness, redness, swelling, peeling, itching, burning or stinging, and that it can cause photosensitivity, and the patient information asks users to tell their healthcare provider about any side effect that bothers them or does not go away [9]. If you use tretinoin or another prescription retinoid, tell both your procedure provider and your prescriber about the appointment, and let them agree on the plan.
Understanding vitamin C around open microchannels
Vitamin C has a strong reputation in skincare, and the scientific reviews are more measured. Pullar and colleagues reported in 2017 that normal skin holds high concentrations of vitamin C and described the benefit of applying it to the skin, as opposed to getting it from diet, as poorly understood [13]; Al-Niaimi and Chiang described clinical studies of topical vitamin C as limited the same year [14].
The microneedling reports are the reason many practices ask about vitamin C in particular. Soltani-Arabshahi and colleagues described three women in 2014 who developed facial granulomas, a firm inflammatory reaction in the skin, after microneedling; two had the same branded vitamin C serum applied during the procedure, the first two patients had a positive patch test to that serum, and the authors concluded that topical products applied before microneedling can introduce immunogenic particles into the dermis [5].
Friedmann and colleagues gathered the published cases in a 2025 systematic review and found 15 patients across 13 reports, with motorized microneedling pens and topical vitamin C implicated in most of them [4]. The reviewers concluded that these reactions can rarely occur [4].
A controlled trial adds a different data point for one formulation. Liu and colleagues reported in 2026 a trial that randomized 31 adults to a vitamin C, E and ferulic acid serum on one side of the face and a placebo serum on the other after microneedling, with greater improvement on the serum side and only mild, transient side effects; two of the authors list affiliations with the serum’s brand [6].
The FDA’s microneedling page states that microneedling devices are not approved for delivery of cosmetics, topical medications, vitamin solutions, drugs or blood products into the skin [18]. Whether any vitamin C product goes on before, during or after a session is your provider’s call, and the published reports explain why they will want to know exactly which product you use at home.
Exosome material is applied in the clinic during the session
In the controlled facial studies, exosome material is applied by the practitioner as part of the session. Park and colleagues ran a randomized split-face study in 28 adults in 2023, applying an exosome-containing solution to one side of the face and saline to the other with each of three microneedling sessions [17].
That timing places the exosome step inside the days your provider plans your home routine around, so exosomes before or after retinol usually comes down to when your home routine restarts. Gaebe and colleagues reviewed 16 facial studies with 503 participants in 2026 and reported that no serious adverse events were reported, while rating the certainty of the evidence low or very low [16].
ExaVeyra exosome material ships frozen from the manufacturing facility in every available format, and every vial carries its lot number. A certificate of analysis is generated for every lot and is available on request, together with the characterization panel and cold-chain records, so your provider can answer questions about the exact material used at your appointment.
Summarizing what the published sources report for each product
The table sets the products in a typical home routine beside the exosome step, with what the cited sources report and who makes the call around an appointment. Every row ends with a person, because every row is a decision for your own provider or prescriber.
| Product | Category | What the published sources report | Who decides around an appointment |
|---|---|---|---|
| Retinol serum or cream | Usually sold as skincare; the FDA says category follows intended use [12] | Changes similar in kind to retinoic acid but tending to be smaller (Kong 2016 [10]); considerably less irritating than tretinoin (Mukherjee 2006 [11]) | Your procedure provider |
| Topical tretinoin | FDA-approved prescription drug [9] | The label lists dryness, redness, swelling, peeling, itching, burning or stinging, and photosensitivity [9] | Your prescriber, together with your procedure provider |
| Oral isotretinoin | FDA-approved prescription drug | Evidence found insufficient to delay superficial chemical peels and nonablative lasers (Waldman 2017 [8]; Spring 2017 [7]) | Your prescriber |
| Vitamin C serum | Usually sold as skincare | Granulomatous reactions after microneedling, which can rarely occur (Friedmann 2025 [4]); a 31-person split-face trial of one serum reported only mild, transient side effects (Liu 2026 [6]) | Your procedure provider |
| Exosome material | No FDA-approved exosome products (FDA 2019 [19]) | No serious adverse events reported across 16 facial studies, with low or very low certainty (Gaebe 2026 [16]) | Your practitioner, who applies it in the clinic |
Understanding what the evidence does not yet show
The guidance on home actives around procedures is careful and still thin, and its gaps are specific enough to list. Each one is a question future studies can answer.
- No located study has tested the timing of exosome material applied at a procedure against a home retinol, tretinoin or vitamin C routine.
- Nikolis and colleagues reported in 2026 that very few studies compared a skincare routine with no skincare, and their recommendations combine the literature with the panel’s own experience [1].
- Gold and colleagues reported in 2020 that no standard of care for skin preparation or aftercare was observed across the responding practices [2].
- The vitamin C reaction reports are case reports and a review of 15 patients, which shows the reaction can happen without showing how often [4, 5].
- The only located controlled vitamin C serum trial with microneedling, Liu 2026, enrolled 31 participants and included authors affiliated with the serum brand [6].
- The 2017 retinoid timing reviews concern oral isotretinoin, so their conclusions apply only indirectly to topical retinol or tretinoin [7, 8].
- Gaebe and colleagues rated the certainty of the facial exosome evidence low or very low in 2026 [16].
Preparing questions for your provider and prescriber
A short conversation before the appointment covers most of what this article describes. These questions work for a first visit and for a repeat one.
- Which of my current products should I pause before the appointment, and for how many days?
- When can I restart retinol afterward, and should I bring it back gradually?
- I use prescription tretinoin. Will you coordinate the plan with my prescriber?
- Should I skip vitamin C or other serums on the day, and which products will you apply during the session?
- Which exosome material will you use, and can I see its lot number and certificate of analysis?
- Which sunscreen and moisturizer would you like me to use in the days after?
- Who should I contact if my skin reacts more than expected?
Bring the products themselves or photos of their labels, since retinol and vitamin C come in many strengths and forms. Your provider can then give instructions for your routine instead of a general rule.
The questions patients ask about retinol, tretinoin and vitamin C around an exosome appointment are good ones, and the clearest answers come from the provider who knows your skin and your prescriptions. ExaVeyra Sciences supplies exosome material to licensed practitioners; every ExaVeyra certificate of analysis reports serological testing for pathogens, and miRNA characterization data is available on request. As more studies document home routines alongside in-clinic sessions these answers will grow more precise, and a licensed practitioner near you is the right place to start. Anyone can ask the scientific team a question or apply without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing, so a practice that wants to carry exosome material can apply for a verified account today.
Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
References
- 1.Nikolis A, Nestor MS, Czuwara J, Depfenhart M, Fluhr JW, Addor FASA, et al. Concomitant Use of Dermo-Cosmetic Skin Care in Aesthetic Procedures: Systematic Review with Expert Panel Recommendations. Clin Cosmet Investig Dermatol. 2026;19:577128. PMID 41773167. PMC12949975. doi:10.2147/CCID.S577128Systematic literature review through June 2022 (104 publications) with an expert panel of six dermatologists and two plastic surgeons. Carries in this article: the most recent published guidance on skincare before and after aesthetic procedures, its list of common periprocedural products, its own finding that very few studies compared a routine with no skincare, its note that microneedling micropores may need several days before the barrier is completely restored, and its peel recommendations (preprocedural tretinoin for lighter skin; retinoids stopped 1 to 2 weeks before peeling in darker skin). Disclosure: five authors are employees of a dermatology and skincare company that the panel members also report ties to.
- 2.Gold MH, Andriessen A, Goldberg DJ, Grover KV, Hu S, Lorenc ZP, et al. Pre-/postprocedure measures for minimally invasive, nonenergy aesthetic treatments: A survey. J Cosmet Dermatol. 2020;19(7):1587-1592. PMID 32521124. doi:10.1111/jocd.13460Electronic survey of 2,000 dermatologists and 388 plastic surgeons, February to May 2019; 109 completed surveys. Carries in this article: the finding that skin preparation and aftercare for microneedling, peels and similar procedures varied between practices with no standard observed. Disclosure: one author is affiliated with a contract development and manufacturing company; no funding statement in the PubMed record.
- 3.Alster TS, Graham PM. Microneedling: A Review and Practical Guide. Dermatol Surg. 2018;44(3):397-404. PMID 28796657. doi:10.1097/DSS.0000000000001248Narrative literature review with a practical technique guide drawn from the authors’ clinical experience. Carries in this article: a published example of microneedling guidance that sets out pretreatment recommendations and post-procedure considerations as part of the procedure itself. Disclosure: no COI statement in the PubMed record.
- 4.Friedmann DP, Mehta E, Verma KK, Harris R. Granulomatous Reactions From Microneedling: A Systematic Review of the Literature. Dermatol Surg. 2025;51(3):263-266. PMID 39584690. doi:10.1097/DSS.0000000000004450Systematic review of four databases; 13 studies describing 15 patients aged 26 to 74. Carries in this article: granulomatous reactions after microneedling can rarely occur, and motorized pens and topical vitamin C application were implicated in most reported cases. Disclosure: no COI statement in the PubMed record.
- 5.Soltani-Arabshahi R, Wong JW, Duffy KL, Powell DL. Facial allergic granulomatous reaction and systemic hypersensitivity associated with microneedle therapy for skin rejuvenation. JAMA Dermatol. 2014;150(1):68-72. PMID 24258303. doi:10.1001/jamadermatol.2013.6955Case series of three women (USA). Carries in this article: two of the three had the same branded vitamin C serum applied during microneedling, the first two patients had a positive patch test reaction to it, and the authors concluded that topical products applied before microneedling can introduce immunogenic particles into the dermis. Disclosure: academic authors; no COI statement in the PubMed record.
- 6.Liu C, Boo J, Kim H, Hwang S, Yan X, Brieva P, et al. A Double-Blinded, Split-Face Clinical Trial Evaluating the Effects of a Vitamin C, E, and Ferulic Acid Serum Combined with Microneedling on Facial Photoaging. Clin Cosmet Investig Dermatol. 2026;19:565035. PMID 41710525. PMC12912124. doi:10.2147/CCID.S565035Prospective, randomized, double-blinded split-face trial over 12 weeks, microneedling at baseline and week 4 with an antioxidant serum on one side and placebo serum on the other; adults with signs of facial aging; n = 31. Carries in this article: the controlled counterpoint to the case reports, with only mild, transient side effects reported for that formulation. Disclosure: two authors list affiliations with the serum’s brand; one author reports consulting and speaker fees from other companies.
- 7.Spring LK, Krakowski AC, Alam M, Bhatia A, Brauer J, Cohen J, et al. Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. JAMA Dermatol. 2017;153(8):802-809. PMID 28658462. doi:10.1001/jamadermatol.2017.2077Systematic review of English-language literature from 1982 to 2017 with graded evidence and national expert consensus; 32 publications reporting 1,485 procedures. Carries in this article: an example of how published guidance on retinoid timing around procedures has been revisited, and why timing decisions sit with the prescriber. Disclosure: academic and practice authors; no COI statement in the PubMed record.
- 8.Waldman A, Bolotin D, Arndt KA, Dover JS, Geronemus RG, Chapas A, et al. ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use. Dermatol Surg. 2017;43(10):1249-1262. PMID 28498204. doi:10.1097/DSS.0000000000001166American Society for Dermatologic Surgery task force: literature extraction, clinical question review, Delphi consensus and peer validation. Carries in this article: the package insert language advising a six-month gap before cosmetic procedures, and the task force conclusion that evidence was insufficient to justify delaying superficial peels and nonablative lasers. Disclosure: no COI statement in the PubMed record.
- 9.Bausch Health US, LLC. RETIN-A MICRO (tretinoin) gel, microsphere, for topical use. Prescribing information and patient information, labeling supplement S-029 approved 10 September 2025. NDA 020475. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020475Orig1s029lbl.pdf and https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020475FDA-approved labeling for a prescription tretinoin product (Drugs@FDA application page, label PDF and openFDA record, verified 9 November 2026). Carries in this article: the label states that tretinoin can cause local skin irritation, including excessive dryness, redness, swelling, peeling, itching, blistering, burning or stinging, and can cause photosensitivity, and the patient information asks users to tell their healthcare provider about any side effect that bothers them or does not go away. Label holder document.
- 10.Kong R, Cui Y, Fisher GJ, Wang X, Chen Y, Schneider LM, et al. A comparative study of the effects of retinol and retinoic acid on histological, molecular, and clinical properties of human skin. J Cosmet Dermatol. 2016;15(1):49-57. PMID 26578346. doi:10.1111/jocd.12193Comparative human study with biopsies, confocal imaging and gene and protein analysis over four weeks, plus a 12-week retinol facial imaging study. Carries in this article: retinol produced changes similar in kind to retinoic acid (the active form of tretinoin) but smaller in magnitude. Disclosure: five of the seven authors are affiliated with a consumer products company’s research and development division.
- 11.Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-48. PMID 18046911. PMC2699641. doi:10.2147/ciia.2006.1.4.327Narrative review of natural and synthetic retinoids, cited in addition to the recent set. Carries in this article: the reviewers described burning, scaling and irritation as the main limit on retinoid use, more prominent with tretinoin and tazarotene than with retinaldehyde and retinol. Disclosure: academic authors; no COI statement in the PubMed record.
- 12.U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). Content current as of 09/11/2024; verified 9 November 2026. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soapFDA consumer and industry explainer of the Federal Food, Drug, and Cosmetic Act definitions. Carries in this article: the agency explains that whether a product is a cosmetic or a drug under the law is determined by its intended use, the reason a retinol serum and a prescription tretinoin sit in different categories.
- 13.Pullar JM, Carr AC, Vissers MCM. The Roles of Vitamin C in Skin Health. Nutrients. 2017;9(8):866. PMID 28805671. PMC5579659. doi:10.3390/nu9080866Narrative review of in vitro and in vivo research on vitamin C in skin. Carries in this article: skin holds high concentrations of vitamin C, and the reviewers described the benefit of topical application, as opposed to dietary intake, as poorly understood. Disclosure: partly funded by a food industry company, which the authors state had no influence on the review.
- 14.Al-Niaimi F, Chiang NYZ. Topical Vitamin C and the Skin: Mechanisms of Action and Clinical Applications. J Clin Aesthet Dermatol. 2017;10(7):14-17. PMID 29104718. PMC5605218Narrative review based on a PubMed search of vitamin C forms used on skin. Carries in this article: the reviewers described clinical studies of topical vitamin C as limited and named formulation stability and penetration as the main challenge. Disclosure: no funding; the authors declared no conflicts of interest.
- 15.Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release. 2011;154(2):148-55. PMID 21640148. PMC3164267. doi:10.1016/j.jconrel.2011.05.021Human volunteer study measuring skin impedance after microneedle insertion under occluded and unoccluded conditions. Carries in this article: unoccluded microneedle sites recovered barrier properties within about two hours, while occluded sites stayed permeable for 3 to 40 hours, which is why the first hours after a session are the ones practices plan around. Disclosure: academic study; funding and disclosures are stated in the full text, not the PubMed record.
- 16.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026 Jul 22. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment, searches to June 2025; 16 studies, 503 participants. Carries in this article: no serious adverse events were reported across the facial studies, and the certainty of evidence was rated low or very low. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
- 17.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized split-face study over 12 weeks, three microneedling sessions with an exosome solution on one side and saline on the other; adults (Korea); n = 28. Carries in this article: an example of how a controlled study applies exosome material with microneedling at each session, with no home actives built into the protocol. Disclosure: National Research Foundation of Korea grants; no COI statement in the PubMed record.
- 18.U.S. Food and Drug Administration. Microneedling Devices. Content current as of 10/15/2025; verified 9 November 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devicesFDA device information page for patients and providers. Carries in this article: the agency states that microneedling devices are not approved for delivery of cosmetics, topical medications, vitamin solutions, drugs or blood products into the skin.
- 19.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsFDA public safety notification. Carries in this article: the agency stated that there are currently no FDA-approved exosome products, the regulatory position the article states in its callout.